Vanguard National Trust’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-70
Closed -$12.1K 794
2026
Q1
$12.1K Buy
+70
New +$13K ﹤0.01% 532

Other funds holding CRL

Vanguard National Trust's CRL Position: Q2 2026 in Review

Vanguard National Trust sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 70 shares — an estimated $12.1K sold.

Vanguard National Trust first reported a position in CRL in Q1 2026 and held it in 1 quarter. The position peaked at $12.1K in Q1 2026. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Vanguard National Trust reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Vanguard National Trust sold 70 Charles River Laboratories shares in Q2 2026, an estimated $12.1K.
  • Vanguard National Trust first reported a position in Charles River Laboratories in Q1 2026 and held it in 1 quarter.
  • Vanguard National Trust's Charles River Laboratories position peaked at $12.1K in Q1 2026.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.